金属抗癌药物的研究进展
Yun Bai1, Gerile Aodeng1, Lu Ga2
1Inner Mongolia Key Laboratory of Environmental Chemistry, College of Chemistry and Enviromental Science, Inner Mongolia Normal University, 81 Zhaowudalu, Hohhot 010022, China.
Pharmaceutics
|December 23, 2023
概括
金属抗癌药物为传统化疗提供了有希望的替代品,具有高选择性和低毒性. 本综述探讨了,和其他金属复合物,以改善癌症治疗策略.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 材料科学 材料科学 材料科学
背景情况:
- 传统化疗因耐药性和严重的副作用而面临局限性,治疗患者的生存率很低.
- 开发可替代正常细胞的向癌症疗法仍然是临床瘤学的重大挑战.
- 发现西斯的抗癌性质刺激了对金属制药的研究,这一领域已经成为主要焦点.
研究的目的:
- 对基于金属的抗癌复合物的科学文献进行审查,重点关注它们克服化疗局限性的潜力.
- 突出金属药物的独特药物特性,如复合物,包括选择性和低毒性.
- 概述最近在合成高效和低毒性金属抗瘤复合物的进展.
主要方法:
- 对国内和国际科学出版物的综合文献综述.
- 对金属抗癌复合物的研究分析,包括 (Pt), (Ru), (Ir) 和金 (Au).
- 新型金属抗瘤复合物的合成和特征是从现有研究中引用的.
主要成果:
- 与传统药物相比,基于金属的药物,特别是复合物,具有较高的选择性和较低的毒性.
- 最近的研究导致了高效的金属抗瘤复合物的合成,这些复合物具有改进的治疗特征.
- 经过审查的文献表明,越来越多的证据支持各种金属复合物的癌症治疗潜力.
结论:
- 金属抗癌药物代表了开发更有效,更安全的癌症治疗的有希望的途径.
- 和其他金属复合物具有独特的优势,包括有针对性的作用和减少副作用.
- 基于金属的化疗的进一步研究和开发具有改善瘤学患者治疗结果的巨大潜力.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Electron Transport Chain: Complex I and II
13.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.7K


